Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
Jiangsu Hengrui Medicine Co., Ltd. stock (symbol: 600276.SS) underwent a total of 19 stock splits.
The most recent stock split occured on Jun 10, 2021.
Date | Splite | Multiple |
---|---|---|
2021-06-10 | 6:5 | 6 |
2020-05-25 | 6:5 | 6 |
2019-03-28 | 6:5 | 6 |
2018-05-30 | 13:10 | 13 |
2017-05-31 | 6:5 | 6 |
2016-06-16 | 6:5 | 6 |
2015-06-15 | 13:10 | 13 |
2014-05-15 | 11:10 | 11 |
2013-06-07 | 11:10 | 11 |
2012-05-29 | 11:10 | 11 |
2011-04-26 | 3:2 | 3 |
2010-03-17 | 6:5 | 6 |
2009-04-30 | 6:5 | 6 |
2008-04-11 | 6:5 | 6 |
2007-04-02 | 13:10 | 13 |
2006-08-29 | 13:10 | 13 |
2006-06-19 | 6:5 | 6 |
2002-05-21 | 6:5 | 6 |
2001-05-11 | 13:10 | 13 |